6-Bromo-2-hexyl-2,3-dihydrobenzopyran | 149548-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-Bromo-2-hexyl-2,3-dihydrobenzopyran
• 英文别名: 6-bromo-2-hexylchroman；6-bromo-2-hexyl-3,4-dihydro-2H-chromene
• CAS: 149548-67-4
• 化学式: C₁₅H₂₁BrO
• 分子量: 297.235
• InChiKey: GXLJIDYABPCBCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-Bromo-2-hexyl-2,3-dihydrobenzopyran 在 正丁基锂 、 氯化亚砜 、 三乙胺 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 1.75h， 生成 2-Hexyl-2,3-dihydrobenzopyran-6-carboxylic acid 4-cyanophenyl ester
  参考文献：
  名称：

  Synthesis and Properties of a New Family of Chiral Mesogens Containing the 2,3-Dihydrobenzopyran Nucleus

  摘要：

  A new class of mesogens A with a central chiral core based on the 2,3-dihydrobenzopyran nucleus was synthesized both in the racemic and optically pure form, and the thermotropic properties were studied. The distortion from structural linearity due to the presence of the 2,3-dihydropyran ring does not inhibit the existence of mesophases, and Ch, S-A, and S-C phases were observed according to the substituents present. The conformational constrictions imposed by cyclization proved not to be very important in determining the compactness of the cholesteric helix.

  DOI：

  10.1021/jo00099a022
• 作为产物：
  描述：

  庚酸乙酯 在 palladium on activated charcoal 盐酸 、 氢气 、 溴 作用下， 以 乙醇 为溶剂， 反应 60.0h， 生成 6-Bromo-2-hexyl-2,3-dihydrobenzopyran
  参考文献：
  名称：

  Synthesis and Properties of a New Family of Chiral Mesogens Containing the 2,3-Dihydrobenzopyran Nucleus

  摘要：

  A new class of mesogens A with a central chiral core based on the 2,3-dihydrobenzopyran nucleus was synthesized both in the racemic and optically pure form, and the thermotropic properties were studied. The distortion from structural linearity due to the presence of the 2,3-dihydropyran ring does not inhibit the existence of mesophases, and Ch, S-A, and S-C phases were observed according to the substituents present. The conformational constrictions imposed by cyclization proved not to be very important in determining the compactness of the cholesteric helix.

  DOI：

  10.1021/jo00099a022

文献信息

• [EN] SUBSTITUTED BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016028959A1

  公开（公告）日：2016-02-25

  Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V) and/or a salt thereof, wherein R1 is OH or OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula（I）、（II）、（III）、（IV）和（V）及/或其盐的化合物，其中R1为OH或OP（O）（OH）2，X1、X2、X3、R2、R2a、Ra、Rb和Rc在此处有定义。还揭示了将这些化合物用作选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面是有用的，如自身免疫疾病和血管疾病。
• SUBSTITUTED BICYCLIC COMPOUNDS
  申请人：Bristol-Myers Squibb Company

  公开号：US20160052888A1

  公开（公告）日：2016-02-25

  Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R 1 is —OH or —OP(O)(OH) 2 , and X 1 , X 2 , X 3 , R 2 , R 2a , R a , R b , and R c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  公开了公式（I）、（II）、（III）、（IV）和（V）的化合物及/或其盐，其中R1为—OH或—OP（O）（OH）2，X1、X2、X3、R2、R2a、Ra、Rb和Rc的定义如本文所述。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法，以及包括这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或障碍方面有用，例如自身免疫性疾病和血管疾病。
• Substituted bicyclic compounds
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10166249B2

  公开（公告）日：2019-01-01

  Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  所公开的是式 (I)、(II)、(III)、(IV) 和 (V) 的化合物： 和/或其盐，其中 R1 是-OH 或-OP(O)(OH)2，X1、X2、X3、R2、R2a、Ra、Rb 和 Rc 在本文中定义。还公开了将此类化合物用作 G 蛋白偶联受体 S1P1 选择性激动剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗、预防或减缓各种治疗领域的疾病或失调，如自身免疫性疾病和血管疾病。
• Bonini Bianca F., Carboni Paolo, Gottarelli Giovanni, Masiero Stefano, Sp+, J. Org. Chem, 59 (1994) N 20, S 5930-5936
  作者：Bonini Bianca F., Carboni Paolo, Gottarelli Giovanni, Masiero Stefano, Sp+

  DOI：——

  日期：——
• US9522888B2
  申请人：——

  公开号：US9522888B2

  公开（公告）日：2016-12-20